Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · broad
The model's full reasoning — Q2 2018 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. We need determine if there is positive current development probed in Q&A with additive concrete detail beyond prepared remarks. And broad demand base. Let's parse transcript. Prepared remarks: strong pharma growth, DARZALEX, IMBRUVICA, ZYTIGA, STELARA, TREMFYA, Actelion PAH assets OPSUMIT/UPTRAVI. Medical devices: Interventional Solutions EP growth >17%, Vision 9.6%, contact lens 10.5%, surgical 7.5%. Orthopedics flat, Spine/Knees losing share but improving. Consumer weak. Q&A: Analysts ask about guidance, pharma, devices, REMICADE, Actelion, Spine, etc. Need identify positive current development that management highlights and analysts probe, and Q&A adds more concrete operating detail than prepared remarks. Potential candidates: - Actelion/PAH franchise: Prepared remarks gave OPSUMIT growth 16%, UPTRAVI 41% US, TRACLEER declining. Q&A: David Lewis asks about Actelion growth rate. Joe says overall up about 2%, OPSUMIT/UPTRAVI double-digit, patient assistance foundations not overhang. That's not much new. Later Geoff Meacham asks about UPTRAVI beating consensus, generics. Joe says patient assistance foundation, broader reach. Alex adds transition, team coming together, global selling synergies, medical affairs, identifying patients earlier, combination therapy. This is somewhat additive but qualitative, not concrete operating detail. Not enough. - Medical Devices EP/electrophysiology: Prepared remarks mention >17% growth, new products ablation/advanced catheters. Q&A: David Lewis asks about procedure growth driver, CABANA trial. Joe says too early to determine. No additive detail. So no. - TREMFYA: Prepared remarks: $126 million, 15,000 patients, 5% share. Q&A? Not probed. No. - STELARA: Prepared remarks: up 34%, Crohn's share improved 10 points. Q&A? Not probed. - ZYTIGA: Prepared remarks: up 60%, LATITUDE. Q&A: Larry asks about pharma growth if ZYTIGA loses exclusivity. Alex says remove ZYTIGA still 8% growth, portfolio strong. Not additive about ZYTIGA operations. - Medical Devices overall improvement: Prepared remarks: 2.9% adjusted operational growth, strongest since Q3 2016, Interventional Solutions, Vision, surgery. Q&A: Joanne asks about Spine/Knees, Alex gives qualitative plans. Not positive current development with additive detail. - Consumer? Weak, no.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FTAI | Fortress Transportation and Infrastructu | Q2 2024 | 2024-07-24 | A |
| FYBR | Frontier Communications Parent, Inc. | Q1 2024 | 2024-05-03 | B |
| TOL | Toll Brothers, Inc. | Q1 2024 | 2024-02-21 | A |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | A |
| ZWS | Zurn Elkay Water Solutions Corporation | Q4 2023 | 2024-02-07 | B |
| TMUS | T-Mobile US, Inc. | Q4 2023 | 2024-01-25 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| WEAV | Weave Communications, Inc. | Q3 2023 | 2023-11-01 | B+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| SURG | SurgePays, Inc. | Q2 2023 | 2023-08-12 | D |
| EVLV | Evolv Technologies Holdings, Inc. | Q2 2023 | 2023-08-10 | B+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| NOW | ServiceNow, Inc. | Q2 2023 | 2023-07-26 | A |
| UTHR | United Therapeutics Corporation | Q1 2023 | 2023-05-03 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| MGM | MGM Resorts International | Q1 2023 | 2023-05-01 | A |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| PAYX | Paychex, Inc. | Q3 2023 | 2023-03-29 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | A |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| APLE | Apple Hospitality REIT, Inc. | Q4 2021 | 2022-02-23 | A |
| DV | DoubleVerify Holdings, Inc. | Q3 2021 | 2021-11-11 | B |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| AMH | American Homes 4 Rent | Q3 2021 | 2021-11-05 | B+ |
| BIGC | BigCommerce Holdings, Inc. | Q3 2021 | 2021-11-04 | B+ |
| SPSC | SPS Commerce, Inc. | Q3 2021 | 2021-10-28 | A |
| INBK | First Internet Bancorp | Q3 2021 | 2021-10-21 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| SNY | Sanofi | Q3 2018 | 2018-10-31 | B+ |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | A |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SNDR | Schneider National, Inc. | Q1 2018 | 2018-04-26 | A |
| ROKU | Roku, Inc. | Q4 2017 | 2018-02-21 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | A |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| FIVN | Five9, Inc. | Q4 2016 | 2017-02-17 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| PLNT | Planet Fitness, Inc. | Q4 2015 | 2016-03-03 | A |
| BECN | Beacon Roofing Supply, Inc. | Q1 2016 | 2016-02-05 | B |
APLE · Q4 2021 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a clear positive current development in the company's hotel portfolio recovery, particularly around Q1 2022 demand trends and operational metrics. In prepared remarks, Justin Knight and Liz Perkins highlight overall RevPAR improvement, leisure strength, and business travel recovery, but without granular February specifics.
MKC · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES NO (Gate 2 fails because the Frank’s/French’s growth is repeatedly tied to specific large retailers, national accounts, and one major customer whose shelf-reset decisions and promotional activity are named or implied as key drivers; the transcript never establishes a broad, granular base of many independent counterparties whose small decisions are widening adoption.
GAIA · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a positive current development in organic subscriber growth and the member referral program. Prepared remarks note organic contributions over 40% and reduced marketing spend. Q&A provides additive details: specific referral mechanics (7-day free watch), ambassador program vs.